INTELLIGENT BIO SOLUTIONS INC.
For the period ended Jun 30, 2026. Filed Aug 19, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2026 · Filed Aug 19, 2026
INBS$2.25-1.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
CONSOLIDATED STATEMENTS OF OPERATIONS AND OTHER COMPREHENSIVE INCOME (LOSS)
Intelligent Bio Solutions Inc.
Consolidated Statements of Operations and Other Comprehensive Income (Loss)
| Year ended June 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Revenue | $4,215,175 | $3,052,532 |
| Cost of revenue (exclusive of amortization shown separately below) | (2,165,181) | (1,805,673) |
| Gross profit | 2,049,994 | 1,246,859 |
| Other income | ||
| Government support income | 677,776 | 816,901 |
| Operating expenses | ||
| Selling, general and administrative expenses | (10,502,161) | (8,918,468) |
| Development and regulatory approval expenses | (3,371,292) | (2,396,513) |
| Depreciation and amortization | (1,163,847) | (1,207,875) |
| Impairment of long-lived assets | (298,555) | (220,062) |
| Total operating expenses | (15,335,855) | (12,742,918) |
| Loss from operations | (12,608,085) | (10,679,158) |
| Other income (expense), net | ||
| Interest expense | (10,736) | (26,339) |
| Realized foreign exchange gain (loss) | 39,820 | (911) |
| Interest income | 110,329 | 101,522 |
| Total other income, net | 139,413 | 74,272 |
| Net loss | (12,468,672) | (10,604,886) |
| Net loss attributable to non-controlling interest | (37,697) | (36,153) |
| Net loss attributable to Intelligent Bio Solutions Inc. | $(12,430,975) | $(10,568,733) |
| Other comprehensive (loss) income | ||
| Foreign currency translation (loss) gain | (218,242) | 384,670 |
| Total other comprehensive (loss) income | (218,242) | 384,670 |
| Comprehensive loss | (12,686,914) | (10,220,216) |
| Comprehensive loss attributable to non-controlling interest | (37,697) | (36,153) |
| Comprehensive loss attributable to Intelligent Bio Solutions Inc. | $(12,649,217) | $(10,184,063) |
| Net loss per share, basic and diluted* | $(8.44) | $(20.04) |
| Weighted average shares outstanding, basic and diluted* | 1,472,744 | 527,364 |
| * | Common stock and per share amounts have been retroactively adjusted to reflect a 1-for-10 reverse stock split effected on December 15, 2025, throughout the consolidated financial statements unless otherwise stated. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.